Search results for "MORBIDITY"

showing 10 items of 986 documents

Transdiagnostic neurocognitive deficits in patients with type 2 diabetes mellitus, major depressive disorder, bipolar disorder, and schizophrenia: A …

2021

AbstractBackgroundImpairments in neurocognition are critical factors in patients with major depressive disorder (MDD), bipolar disorder (BD), and schizophrenia (SZ), and also in those with somatic diseases such as type 2 diabetes mellitus (T2DM). Intriguingly, these severe mental illnesses are associated with an increased co-occurrence of diabetes (direct comorbidity). This study sought to investigate the neurocognition and social functioning across T2DM, MDD, BD, and SZ using a transdiagnostic and longitudinal approach.MethodsA total of 165 subjects, including 30 with SZ, 42 with BD, 35 with MDD, 30 with T2DM, and 28 healthy controls (HC), were assessed twice at a 1-year interval using a c…

Longitudinal studySchizophreniabusiness.industryNeuropsychologymedicineMajor depressive disorderBipolar disordermedicine.diseasebusinessNeurocognitiveComorbidityClinical psychologyCognitive reserve
researchProduct

Mapping geographical inequalities in childhood diarrhoeal morbidity and mortality in low-income and middle-income countries, 2000-17: analysis for th…

2020

Background: Across low-income and middle-income countries (LMICs), one in ten deaths in children younger than 5 years is attributable to diarrhoea. The substantial between-country variation in both diarrhoea incidence and mortality is attributable to interventions that protect children, prevent infection, and treat disease. Identifying subnational regions with the highest burden and mapping associated risk factors can aid in reducing preventable childhood diarrhoea. Methods: We used Bayesian model-based geostatistics and a geolocated dataset comprising 15 072 746 children younger than 5 years from 466 surveys in 94 LMICs, in combination with findings of the Global Burden of Diseases, Injuri…

Low income countriesmedicine.medical_treatment030204 cardiovascular system & hematologyGlobal HealthTHERAPYGlobal Burden of Disease0302 clinical medicinePrevalenceGlobal healthMedicineWATER030212 general & internal medicineChildren11 Medical and Health SciencesIncidenceMortality rateIncidence (epidemiology)1. No povertyGeneral Medicine3142 Public health care science environmental and occupational healthDiarrhoea3. Good healthChild PreschoolMiddle income countriesA990 Medicine and Dentistry not elsewhere classifiedTERRITORIESLife Sciences & BiomedicineInfantsDiarrheaAFRICAmedicine.medical_specialtyChildhood deathsRJsanitationDeveloping countryChildhood diarrhoeal morbidityITC-HYBRID03 medical and health sciencesMedicine General & InternalGeneral & Internal MedicineEnvironmental healthSYSTEMATIC ANALYSISLife ScienceHumansHealthcare DisparitiesOral rehydration therapyRisk factorhand washingDeveloping CountriesDisease burdenGlobal NutritionWereldvoedingScience & TechnologySEX-SPECIFIC MORTALITYbusiness.industryCHOLERAPublic healthBayes Theoremdiarrheal diseaseLocal Burden of Disease Diarrhoea CollaboratorsITC-ISI-JOURNAL-ARTICLENAHuman medicineDiarreabusiness
researchProduct

Clinical Utility of Midregional Proadrenomedullin in Patients with COVID-19

2021

Abstract Objective The aim of the study was to assess the role of midregional proadrenomedullin (MR-proADM) in patients with COVID-19. Methods We included 110 patients hospitalized for COVID-19. Biochemical biomarkers, including MR-proADM, were measured at admission. The association of plasma MR-proADM levels with COVID-19 severity, defined as a requirement for mechanical ventilation or in-hospital mortality, was evaluated. Results Patients showed increased levels of MR-proADM. In addition, MR-proADM was higher in patients who died during hospitalization than in patients who survived (median, 2.59 nmol/L; interquartile range, 2.3–2.95 vs median, 0.82 nmol/L; interquartile range, 0.57–1.03; …

Lung DiseasesMalemedicine.medical_specialtySciencemedicine.medical_treatmentMR-proADMClinical BiochemistryComorbidityLabmed/1010Severity of Illness IndexGastroenterologyAdrenomedullinInterquartile rangeInternal medicineSeverity of illnessmedicineHumansAspartate AminotransferasesProtein PrecursorsSurvival analysisAgedRetrospective StudiesMechanical ventilationReceiver operating characteristicbiologyInterleukin-6SARS-CoV-2business.industryPatient SelectionBiochemistry (medical)C-reactive proteinCOVID-19Alanine TransaminaseRetrospective cohort studyMiddle AgedPrognosisSurvival Analysisrespiratory diseaseC-Reactive ProteininflammationHypertensionbiology.proteinbiomarkerBiomarker (medicine)FemaleTriagebusinessBiomarkersAcademicSubjects/MED00690Laboratory Medicine
researchProduct

Handgrip strength and cause-specific and total mortality in older disabled women: exploring the mechanism.

2003

OBJECTIVES: To examine the association between muscle strength and total and cause-specific mortality and the plausible contributing factors to this association, such as presence of diseases commonly underlying mortality, inflammation, nutritional deficiency, physical inactivity, smoking, and depression. DESIGN: Prospective population-based cohort study with mortality surveillance over 5 years. SETTING: Elderly women residing in the eastern half of Baltimore, Maryland, and part of Baltimore County. PARTICIPANTS: Nine hundred nineteen moderately to severely disabled women aged 65 to 101 who participated in handgrip strength testing at baseline as part of the Women's Health and Aging Study. M…

Lung Diseasesmedicine.medical_specialtyPopulationComorbidityRisk AssessmentGrip strengthWeight lossPredictive Value of TestsRisk FactorsInternal medicineHand strengthNeoplasmsMedicineHealth Status IndicatorsHumansDisabled PersonsProspective StudiesMortalityProspective cohort studyeducationGeriatric AssessmentAgedProportional Hazards ModelsAged 80 and overeducation.field_of_studyChi-Square DistributionHand Strengthbusiness.industryInterleukin-6medicine.diseaseComorbidityCardiovascular DiseasesRelative riskBaltimorePhysical therapyFemaleGeriatrics and Gerontologymedicine.symptombusinessCohort studyJournal of the American Geriatrics Society
researchProduct

Impact of Age and Comorbidity on Multimodal Management and Survival from Colorectal Cancer : A Population-Based Study

2021

This retrospective population-based study examined the impact of age and comorbidity burden on multimodal management and survival from colorectal cancer (CRC). From 2000 to 2015, 1479 consecutive patients, who underwent surgical resection for CRC, were reviewed for age-adjusted Charlson comorbidity index (ACCI) including 19 well-defined weighted comorbidities. The impact of ACCI on multimodal management and survival was compared between low (score 0–2), intermediate (score 3) and high ACCI (score ≥ 4) groups. Changes in treatment from 2000 to 2015 were seen next to a major increase of laparoscopic surgery, increased use of adjuvant chemotherapy and an intensified treatment of metastatic dis…

MESOCOLIC EXCISIONPREDICTORCARCINOMASURGERYRcolorectal cancersuolistosyövätCO-MORBIDITY3126 Surgery anesthesiology intensive care radiologyPOSTOPERATIVE MORTALITYGUIDELINESelderlysurvivalArticleLIVER METASTASEScomorbidityCOLON3121 General medicine internal medicine and other clinical medicineMedicinesyöpätaudithenkiinjääminenINDEXikääntyneetkomorbiditeetti
researchProduct

Depression comorbid with tuberculosis and its impact on health status: cross-sectional analysis of community-based data from 48 low- and middle-incom…

2017

Background Depression in tuberculosis increases the risk for adverse health outcomes. However, little is known about comorbid depression and tuberculosis in the general population. Thus, we assessed the association between depression and tuberculosis, and the decrements in health status associated with this comorbidity in 48 low- and middle-income countries. Methods Cross-sectional, community-based data from the World Health Survey on 242,952 individuals aged ≥ 18 years were analyzed. Based on the World Mental Health Survey version of the Composite International Diagnostic Interview, past 12-month depression was categorized into depressive episode, brief depressive episode, subsyndromal dep…

Male*Low- and middle-income countriesEpidemiologyHealth Statuslcsh:MedicineComorbidity*EpidemiologyGlobal Health0302 clinical medicineRisk FactorsEpidemiologyPrevalenceNot known030212 general & internal medicineDepressió psíquicaDepression (differential diagnoses)education.field_of_studyLow- and middle-income countriesDepressionGeneral MedicineMiddle Aged3. Good healthMental depressionIncomeFemaleResearch ArticleManagement of depressionAdultDepression; Epidemiology; Low- and middle-income countries; Tuberculosismedicine.medical_specialtyTuberculosisTuberculosiPopulationPain03 medical and health sciencesComorbiditatmedicineHumansTuberculosisEpidemiologiaPsychiatryeducationAgedbusiness.industryPublic healthlcsh:R*Depressionmedicine.diseaseHealth SurveysMental healthComorbiditySelf CareCross-Sectional StudiesSocial Classbusiness*Tuberculosis030217 neurology & neurosurgeryBMC Medicine
researchProduct

Food availability and competition do not modulate the costs of Plasmodium infection in dominant male canaries.

2013

7 pages; International audience; Understanding the different factors that may influence parasite virulence is of fundamental interest to ecologists and evolutionary biologists. It has recently been demonstrated that parasite virulence may occur partly through manipulation of host competitive ability. Differences in competitive ability associated with the social status (dominant or subordinate) of a host may determine the extent of this competition-mediated parasite virulence. We proposed that differences between subordinate and dominant birds in the physiological costs of infection may change depending on the level of competition in social groups. We observed flocks of domestic canaries to …

Male0106 biological sciencesPlasmodiumCanariesParasitemia01 natural sciencesFood Supply[ SDV.EE.IEO ] Life Sciences [q-bio]/Ecology environment/SymbiosisParasite hostingmedia_common0303 health sciencesbiologyVirulenceEcologyFood availabilitySocial stressPlasmodium relictumGeneral MedicineGroup livingInfectious DiseasesAvian malariaInfectionCompetitive Behavior[ SDV.MP.PAR ] Life Sciences [q-bio]/Microbiology and Parasitology/ParasitologyMalaria Avianmedia_common.quotation_subjectImmunologyVirulence010603 evolutionary biologyCompetition (biology)03 medical and health sciencesAvian malariamedicineAnimals[SDV.MP.PAR]Life Sciences [q-bio]/Microbiology and Parasitology/Parasitology030304 developmental biologySocial stress[ SDE.BE ] Environmental Sciences/Biodiversity and EcologySGS1CompetitionFeeding Behaviormedicine.diseasebiology.organism_classificationPlasmodium relictumSocial rankSocial DominanceParasitologyFlockMorbidity[SDE.BE]Environmental Sciences/Biodiversity and Ecology[SDV.EE.IEO]Life Sciences [q-bio]/Ecology environment/Symbiosis
researchProduct

Treatment of Venous Thromboembolism in Special Populations with Direct Oral Anticoagulants

2020

AbstractAs a result of the successful completion of their respective phase III studies compared with vitamin K antagonists (VKAs), four direct oral anticoagulants (DOACs) have been approved for the treatment and secondary prevention of venous thromboembolism (VTE). These DOACs—apixaban, dabigatran, edoxaban, and rivaroxaban—have subsequently seen a steady uptake among clinicians since their approval. Despite the suitability of DOACs for a broad range of patients, they are not appropriate in certain situations, whereas in others they require additional considerations such as dose reductions. Subanalyses of phase III trials and studies on specific VTE patient populations have been conducted t…

Male0301 basic medicineComorbidity030204 cardiovascular system & hematologychemistry.chemical_compound0302 clinical medicinePregnancyEdoxabanNeoplasmsSecondary PreventionChildspecial populationsAge FactorsVenous ThromboembolismHematologyMiddle AgedTreatment OutcomePractice Guidelines as TopicFemaleKidney Diseasesmedicine.drugAdultmedicine.medical_specialtyMEDLINEHemorrhagecomorbiditiesdirect oral anticoagulantsDabigatran03 medical and health sciencesmedicineHumansLactationDosingIntensive care medicineAgedDose-Response Relationship Drugbusiness.industryPatient SelectionPregnancy Complications HematologicContraindications DrugAnticoagulantsmedicine.diseaseComorbidityReview articleClinical trial030104 developmental biologyClinical Trials Phase III as TopicchemistrybusinessVenous thromboembolismFactor Xa InhibitorsThrombosis and Haemostasis
researchProduct

Gender as a Modifying Factor Influencing Myotonic Dystrophy Type 1 Phenotype Severity and Mortality: A Nationwide Multiple Databases Cross-Sectional …

2016

International audience; BACKGROUND: Myotonic Dystrophy type 1 (DM1) is one of the most heterogeneous hereditary disease in terms of age of onset, clinical manifestations, and severity, challenging both medical management and clinical trials. The CTG expansion size is the main factor determining the age of onset although no factor can finely predict phenotype and prognosis. Differences between males and females have not been specifically reported. Our aim is to study gender impact on DM1 phenotype and severity.METHODS: We first performed cross-sectional analysis of main multiorgan clinical parameters in 1409 adult DM1 patients (\textgreater18y) from the DM-Scope nationwide registry and obser…

Male0301 basic medicineDatabases FactualPhysiologyCross-sectional studyMyotonic dystrophylcsh:MedicineDiseasecomputer.software_genreinfo:eu-repo/classification/mesh/Socioeconomic FactorsLaryngologyinfo:eu-repo/classification/mesh/Myotonic Dystrophy/epidemiology*0302 clinical medicineMedicine and Health SciencesEthnicitiesMedicineinfo:eu-repo/classification/mesh/FemaleFrench Peoplelcsh:Scienceinfo:eu-repo/classification/mesh/Adulteducation.field_of_studyMultidisciplinaryinfo:eu-repo/classification/mesh/Factual*Death ratesDatabaseCognitive NeurologyMortality rateDysphagia3. Good healthPhenotypeCognitive impairmentNeurologyPhysiological ParametersFemaleinfo:eu-repo/classification/mesh/Databasesinfo:eu-repo/classification/mesh/MaleResearch ArticleAdultMaternal inheritanceCognitive NeurosciencePopulation[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human geneticsMyotonic dystrophy03 medical and health sciencesPopulation MetricsAdultsHumansObesitySex DistributioneducationDemographyinfo:eu-repo/classification/mesh/Cross-Sectional StudiesPopulation BiologyCataractsbusiness.industrylcsh:RBody WeightBiology and Life Sciencesmedicine.diseaseMyotoniaThyroid disorderinfo:eu-repo/classification/mesh/Sex DistributionHealth CareOphthalmologyCross-Sectional Studies030104 developmental biologyOtorhinolaryngologySocioeconomic Factors[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsAge Groups[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieLens DisordersPeople and Placesinfo:eu-repo/classification/mesh/Myotonic Dystrophy/mortalityCognitive Sciencelcsh:QPopulation Groupings[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieHealth StatisticsMorbidityAge of onsetbusinessinfo:eu-repo/classification/mesh/Phenotype*computerinfo:eu-repo/classification/mesh/Humans030217 neurology & neurosurgeryNeurosciencePLOS ONE
researchProduct

The relationship between Polypharmacy and Trajectories of Cognitive Decline in People with Dementia: a large representative cohort study

2019

Polypharmacy, defined through the number of medications prescribed, has been linked to a range of adverse health outcomes in people with dementia. It is however unclear whether a numerical threshold of concurrently prescribed drugs is a suitable predictor for cognitive decline. We aimed to test associations between polypharmacy and both short-term (six months) and long-term (three years) cognitive trajectories in patients with incident dementia. Using data from a large mental health and dementia care database in South London, a cohort of 12,148 patients (mean age = 80.7 years, 61.1% female, mean MMSE = 18.6) clinically diagnosed with dementia was identified. We determined the number of medi…

Male0301 basic medicineGerontologyAgingCognitive declineBiochemistryCohort Studies03 medical and health sciencesCognitionCommunity care0302 clinical medicineEndocrinologyA large representative cohort study.- Experimental gerontology cilt.120 ss.62-67 2019 [Soysal P. Perera G. Isik A. Onder G. Petrovic M. Cherubini A. Maggi S. Shetty H. Molokhia M. Smith L. et al. -The relationship between polypharmacy and trajectories of cognitive decline in people with dementia]mental disordersGeneticsmedicineHumansDementiaCognitive DysfunctionCognitive declineassociations between polypharmacyMolecular BiologyAgedAged 80 and overPolypharmacypeople with dementia.Mini–Mental State Examinationmedicine.diagnostic_testbusiness.industryCognition; Cognitive decline; Community care; Dementia; PolypharmacyCognitionlong-term (three years)Cell BiologyMental Status and Dementia Testsmedicine.diseaseComorbidity030104 developmental biologyCohortPolypharmacyFemaleDementiabusinessshort-term (six months)030217 neurology & neurosurgeryCohort study
researchProduct